Teva Pharmaceutical Industries Limited Stock price

Equities

TEVA

US8816242098

Pharmaceuticals

Real-time Estimate Cboe BZX 02:55:26 2024-03-28 pm EDT 5-day change 1st Jan Change
14.1 USD -2.32% Intraday chart for Teva Pharmaceutical Industries Limited +2.29% +34.72%
Sales 2024 * 15.86B Sales 2025 * 16.28B Capitalization 16.18B
Net income 2024 * 420M Net income 2025 * 743M EV / Sales 2024 * 1.94 x
Net Debt 2024 * 14.62B Net Debt 2025 * 12.12B EV / Sales 2025 * 1.74 x
P/E ratio 2024 *
19.9 x
P/E ratio 2025 *
15.4 x
Employees 35,737
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.57%
More Fundamentals * Assessed data
Dynamic Chart
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $657,240, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,048,119, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,352,090, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $414,270, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,277,207, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $270,176, According to a Recent SEC Filing MT
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs... Our Logo
Alvotech, Teva Say Simlandi Receives US FDA Approval as Interchangeable Humira Biosimilar MT
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week MT
Teva Pharmaceutical's TEV-'574 Antibody Found to Be Safe in Studies MT
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO RE
Teva Pharmaceutical Shares Rise After Piper Sandler Upgrade MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12 MT
High-dose opioid reversal spray no better than lower dose in field, US study finds RE
More news

Latest transcript on Teva Pharmaceutical Industries Limited

1 day+2.05%
1 week+7.05%
Current month+9.73%
1 month+8.50%
3 months+37.04%
6 months+44.16%
Current year+38.22%
More quotes
1 week
13.69
Extreme 13.69
14.45
1 month
13.01
Extreme 13.005
14.45
Current year
10.45
Extreme 10.45
14.45
1 year
7.09
Extreme 7.085
14.45
3 years
6.78
Extreme 6.7791
14.45
5 years
6.07
Extreme 6.07
15.91
10 years
6.07
Extreme 6.07
72.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 22-12-31
Director of Finance/CFO 51 19-12-21
Chief Tech/Sci/R&D Officer - 22-07-31
Members of the board TitleAgeSince
Director/Board Member 77 15-08-31
Director/Board Member 60 20-06-08
Chairman 76 14-12-31
More insiders
Date Price Change Volume
24-03-28 14.06 -2.53% 6 600 389
24-03-27 14.43 +2.05% 12,252,173
24-03-26 14.14 +0.57% 7,542,987
24-03-25 14.06 +1.22% 8,037,381
24-03-22 13.89 +1.02% 9,282,574

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Teva Pharmaceutical Industries Limited is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
14.43 USD
Average target price
15.15 USD
Spread / Average Target
+4.99%
Consensus
  1. Stock
  2. Equities
  3. Stock Teva Pharmaceutical Industries Limited - Nyse